A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. Kim MS, Banerjee T, Chen A, Danilov A, et al. Leuk Lymphoma 2022 Mar 9:1-3. doi: 10.1080/10428194.2022.2045598.

Read + Share

Amedeo Smart

Independent Medical Education

Kim MS, Banerjee T, Chen A, Danilov A, et al. A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. Leuk Lymphoma 2022 Mar 9:1-3. doi: 10.1080/10428194.2022.2045598.
PMID: 35263204